



## Enovis Announces Second Quarter 2025 Results

August 7, 2025

- **Continued commercial momentum with second-quarter sales growth of 7% on a reported basis**
- **Second-quarter Reconstructive sales grew 11% year-over-year on a reported basis**

Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

### Second Quarter 2025 Financial Results

Enovis' second-quarter net sales of \$565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter in 2024. Second quarter results reflect continued execution in P&R and Recon, stable end markets, and encouraging momentum in new product introductions. Compared to the same quarter in 2024, net sales in Recon grew 11% on a reported basis and 8% on an organic basis, and P&R grew 5% on a reported basis and 3% on an organic basis.

Enovis also reported second-quarter net loss of \$37 million, or a loss of 6.5% of sales, and adjusted EBITDA of \$97 million, or 17.2% of sales.

The Company reported second-quarter 2025 net loss from continuing operations of \$0.64 per share and adjusted net earnings per diluted share of \$0.79.

Damien McDonald, Chief Executive Officer of Enovis, said, "My first 90 days have strengthened my belief that Enovis has the foundation, portfolio, and momentum to drive durable, profitable growth. Realizing this potential will require continued operational discipline and a sharp focus on scalable, capital efficient execution. We are in the early stages of unlocking the full value of our orthopedic platform, and I'm excited to lead the Company with a commitment to continue helping millions of people lead full, active lives with a focus on creating shareholder value. Our second-quarter performance reflects the strength of our diversified global portfolio and the opportunity ahead. I'm grateful to the Board and the entire Enovis team for their support and alignment on our strategy."

### 2025 Financial Outlook

Enovis updated financial expectations for 2025. Revenue is expected to be in the range of \$2.245-2.275 billion, versus prior expectations of \$2.220-2.250 billion. Adjusted EBITDA is forecasted to be \$392-402 million, as compared to the prior outlook of \$385-395 million. Full-year adjusted earnings per share guidance was updated from \$2.95-3.10 to \$3.05-3.20.

### Conference call and Webcast

Investors can access the webcast via a link on the Enovis website, [www.enovis.com](http://www.enovis.com). For those planning to participate on the call, please dial (833) 685-0901. A link to a replay of the call will also be available on the Enovis website later in the day.

### About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit [www.enovis.com](http://www.enovis.com).

### Availability of Information on the Enovis Website

Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on [ir.enovis.com](http://ir.enovis.com).

### Forward-Looking Statements

*This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis' current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis' results to differ materially from current expectations include, but are not limited to, risks related to Enovis' acquisition of Lima; the impact of public health emergencies and global pandemics; disruptions in the global economy caused by escalating geopolitical tensions including in connection with Russia's invasion of Ukraine; macroeconomic conditions, including the impact of inflationary pressures; changes in government trade policies, including the implementation of tariffs; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; other impacts on Enovis' business and ability to execute business continuity plans; and*

the other factors detailed in Enovis' reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K under the caption "Risk Factors," as well as the other risks discussed in Enovis' filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

### Non-GAAP Financial Measures

Enovis has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations ("Adjusted net income"), Adjusted net income per diluted share, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross profit, and Adjusted gross profit margin.

Adjusted net income and Adjusted net income per diluted share exclude net income attributable to noncontrolling interest from continuing operations, net of taxes; the effect of Loss from discontinued operations, net of taxes; restructuring charges; Medical Device Regulation ("MDR") fees and other costs; strategic transaction costs; stock-based compensation; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; property plant and equipment step-up depreciation, and fair value charges on acquired inventory; Other (income) expense, net; and include the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents Adjusted net income margin, which is subject to the same adjustments as Adjusted net income.

Adjusted EBITDA represents Adjusted net income excluding interest, taxes, and depreciation and other amortization. Enovis presents Adjusted EBITDA margin, which is subject to the same adjustments as Adjusted EBITDA.

Adjusted gross profit represents gross profit excluding the fair value charges of acquired inventory, depreciation step-up of acquired fixed assets, and the impact of restructuring charges. Adjusted gross profit margin is subject to the same adjustments as Adjusted gross profit.

Organic sales growth calculates sales growth period over period, after excluding the impact of acquisitions, divestitures, and foreign exchange rate fluctuations.

These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.

Kyle Rose  
Vice President, Investor Relations  
Enovis Corporation  
+1-917-734-7450  
[investorrelations@enovis.com](mailto:investorrelations@enovis.com)

**Enovis Corporation**  
**Condensed Consolidated Statements of Operations**  
Dollars in thousands, except per share data  
(Unaudited)

	Three Months Ended		Six Months Ended	
	July 4, 2025	June 28, 2024	July 4, 2025	June 28, 2024
Net sales	\$ 564,545	\$ 525,160	\$ 1,123,379	\$ 1,041,426
Cost of sales	229,848	236,277	456,453	454,647
Gross profit	334,697	288,883	666,926	586,779
Gross profit margin	59.3 %	55.0 %	59.4 %	56.3 %
Selling, general and administrative expense	267,074	264,100	536,093	519,791
Research and development expense	30,700	23,479	59,228	46,856
Amortization of acquired intangibles	42,962	40,936	84,774	81,867
Purchase of royalty interest	10,041	—	45,818	—
Restructuring charges	716	4,587	4,578	17,498
Operating loss	(16,796 )	(44,219 )	(63,565 )	(79,233 )
Operating loss margin	(3.0) %	(8.4) %	(5.7) %	(7.6) %
Interest expense, net	9,294	16,969	18,482	36,965
Other expense (income), net	(436 )	(33,836 )	956	(9,601 )
Loss from continuing operations before income taxes	(25,654 )	(27,352 )	(83,003 )	(106,597 )
Income tax expense (benefit)	10,801	(8,908 )	9,032	(16,312 )
Net loss from continuing operations	(36,455 )	(18,444 )	(92,035 )	(90,285 )
Loss from discontinued operations, net of taxes	(93 )	(68 )	(218 )	(68 )

Net loss	(36,548 )	(18,512 )	(92,253 )	(90,353 )
Net loss margin	(6.5) %	(3.5) %	(8.2) %	(8.7) %
Less: net income attributable to noncontrolling interest from continuing operations - net of taxes	191	126	452	283
Net loss attributable to Enovis Corporation	<u>\$ (36,739 )</u>	<u>\$ (18,638 )</u>	<u>\$ (92,705 )</u>	<u>\$ (90,636 )</u>
<i>Net income (loss) per share - basic and diluted</i>				
Continuing operations	<u>\$ (0.64 )</u>	<u>\$ (0.34 )</u>	<u>\$ (1.62 )</u>	<u>\$ (1.65 )</u>
Discontinued operations	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>
Consolidated operations	<u>\$ (0.64 )</u>	<u>\$ (0.34 )</u>	<u>\$ (1.62 )</u>	<u>\$ (1.65 )</u>

**Enovis Corporation**  
**Reconciliation of GAAP to Non-GAAP Financial Measures**  
**Dollars in millions, except per share data**  
**(Unaudited)**

	Three Months Ended		Six Months Ended	
	July 4, 2025	June 28, 2024	July 4, 2025	June 28, 2024
<b>Adjusted Net Income and Adjusted Net Income Per Share</b>				
Net Loss (GAAP)	\$ (36.5 )	\$ (18.5 )	\$ (92.3 )	\$ (90.4 )
<i>Net loss margin (GAAP)</i>	(6.5) %	(3.5) %	(8.2) %	(8.7) %
Net income attributable to noncontrolling interest from continuing operations - net of taxes	(0.2 )	(0.1 )	(0.5 )	(0.3 )
Loss from discontinued operations, net of taxes	0.1	0.1	0.2	0.1
Net loss from continuing operations attributable to Enovis Corporation <sup>(1)</sup> (GAAP)	<u>\$ (36.6 )</u>	<u>\$ (18.6 )</u>	<u>\$ (92.5 )</u>	<u>\$ (90.6 )</u>
Restructuring charges - pretax <sup>(2)</sup>	0.9	4.6	4.8	17.5
MDR and other costs - pretax <sup>(3)</sup>	3.3	4.5	6.6	9.5
Amortization of acquired intangibles - pretax	43.0	40.9	84.8	81.9
Inventory step-up and PPE step-up depreciation - pretax <sup>(4)</sup>	6.6	26.1	19.3	31.2
Strategic transaction costs - pretax <sup>(5)</sup>	13.5	22.7	25.5	43.5
Purchase of royalty interest <sup>(6)</sup>	10.0	—	45.8	—
Stock-based compensation	8.7	7.6	16.1	14.0
Other (income) expense, net <sup>(7)</sup>	(0.4 )	(33.8 )	1.0	(9.6 )
Tax adjustment <sup>(8)</sup>	(3.2 )	(19.6 )	(19.2 )	(35.2 )
Adjusted net income from continuing operations (non-GAAP)	<u>\$ 45.7</u>	<u>\$ 34.4</u>	<u>\$ 91.9</u>	<u>\$ 62.0</u>
<i>Adjusted net income margin from continuing operations</i>	8.1 %	6.6 %	8.2 %	6.0 %
Weighted-average shares outstanding - diluted (GAAP)	57,133	54,856	56,960	54,772
Net loss per share - diluted from continuing operations (GAAP)	<u>\$ (0.64 )</u>	<u>\$ (0.34 )</u>	<u>\$ (1.62 )</u>	<u>\$ (1.65 )</u>
Adjusted weighted-average shares outstanding - diluted (non-GAAP)	57,583	55,220	57,476	55,248
Adjusted net income per share - diluted from continuing operations (non-GAAP)	<u>\$ 0.79</u>	<u>\$ 0.62</u>	<u>\$ 1.60</u>	<u>\$ 1.13</u>

(1) Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes.

(2) Restructuring charges include \$0.2 million and \$0.3 million expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three and six months ended July 4, 2025, respectively. There were no similar charges for the three and six months ended June 28, 2024.

(3) MDR and other costs includes (i) \$2.8 million and \$5.4 million for the three and six months ended July 4, 2025 and \$4.4 million and \$8.8 million for the three and six months ended June 28, 2024, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) \$0.4 million and \$1.1 million for the three and six months ended July 4, 2025 and \$0.1 million and \$0.6 million for the three and six months ended June 28, 2024, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(4) Includes \$6.0 million and \$18.1 million in inventory step-up charges and \$0.6 million and \$1.1 million in PPE step-up depreciation in connection with acquired businesses for the three and six months ended July 4, 2025, respectively. Includes \$23.9 million and \$29.0 million in inventory step-up charges in connection with acquired businesses for the three and six months ended June 28, 2024, respectively.

(5) Strategic transaction costs includes: (i) \$7.8 million and \$16.5 million for the three and six months ended July 4, 2025 and \$19.5 million and \$37.7 million for the three and six months ended June 28, 2024, respectively, related to non-recurring integration costs associated with the Lima Acquisition, which includes payroll and retention costs for roles to be eliminated or that are dedicated to integration activities, professional and consulting fees

specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling, and integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) \$5.4 million and \$8.2 million for the three and six months ended July 4, 2025 and \$2.0 million and \$3.0 million for the three and six months ended June 28, 2024, respectively, of non-recurring (non-Lima) acquisition integration costs and other non-recurring project costs for global ERP rationalization and shared service center start-up, and (iii) \$0.3 million and \$0.8 million for the three and six months ended July 4, 2025 and \$1.2 million and \$2.8 million for the three and six months ended June 28, 2024, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(6) In the first and second quarters of 2025, we completed strategic purchases of economic interest on future royalty payments in our intellectual property ("royalty interest") for a fixed price of \$56.5 million, which will be paid over nine years. We accrued a liability and recognized a \$10.0 million and \$45.8 million charge for the net present value of the purchases for the three and six months ended July 4, 2025, respectively.

(7) Other (income) expense, net primarily includes the fair value gain on Contingent Acquisition shares, partially offset by the first quarter of 2024 loss on the non-designated forward currency hedge for managing exchange rate risk related to the Euro-denominated purchase price of the Lima Acquisition.

(8) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 23.4% and 23.4% for the three and six months ended July 4, 2025, respectively, and 23.7% and 23.2% for the three and six months ended June 28, 2024, respectively.

**Enovis Corporation**  
**Reconciliation of GAAP to Non-GAAP Financial Measures**  
**Dollars in millions**  
**(Unaudited)**

	Three Months Ended		Six Months Ended	
	July 4, 2025	June 28, 2024	July 4, 2025	June 28, 2024
	(Dollars in millions)			
Net loss (GAAP)	\$ (36.5 )	\$ (18.5 )	\$ (92.3 )	\$ (90.4 )
Net loss margin (GAAP)	(6.5) %	(3.5) %	(8.2) %	(8.7) %
Loss from discontinued operations, net of taxes	0.1	0.1	0.2	0.1
Income tax expense (benefit)	10.8	(8.9 )	9.0	(16.3 )
Other (income) expense, net	(0.4 )	(33.8 )	1.0	(9.6 )
Interest expense, net	9.3	17.0	18.5	37.0
Operating loss (GAAP)	\$ (16.8 )	\$ (44.1 )	\$ (63.6 )	\$ (79.2 )
Adjusted to add:				
Restructuring charges <sup>(1)</sup>	0.9	4.6	4.8	17.5
MDR and other costs <sup>(2)</sup>	3.3	4.5	6.5	9.5
Strategic transaction costs <sup>(3)</sup>	13.5	22.7	25.5	43.5
Stock-based compensation	8.7	7.6	16.1	14.0
Depreciation and other amortization	28.6	30.1	58.3	57.3
Amortization of acquired intangibles	43.0	40.9	84.8	81.9
Purchase of royalty interest <sup>(4)</sup>	10.0	—	45.8	—
Inventory step-up	6.0	23.9	18.1	29.0
Adjusted EBITDA (non-GAAP)	\$ 97.2	\$ 90.2	\$ 196.3	\$ 173.4
Adjusted EBITDA margin (non-GAAP)	17.2 %	17.2 %	17.5 %	16.7 %

(1) Restructuring charges include \$0.2 million and \$0.3 million expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three and six months ended July 4, 2025, respectively. There were no similar charges for the three and six months ended June 28, 2024.

(2) MDR and other costs includes (i) \$2.8 million and \$5.4 million for the three and six months ended July 4, 2025 and \$4.4 million and \$8.8 million for the three and six months ended June 28, 2024, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) \$0.4 million and \$1.1 million for the three and six months ended July 4, 2025 and \$0.1 million and \$0.6 million for the three and six months ended June 28, 2024, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(3) Strategic transaction costs includes: (i) \$7.8 million and \$16.5 million for the three and six months ended July 4, 2025 and \$19.5 million and \$37.7 million for the three and six months ended June 28, 2024, respectively, related to non-recurring integration costs associated with the Lima Acquisition, which includes payroll and retention costs for roles to be eliminated or that are dedicated to integration activities, professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling, and integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) \$5.4 million and \$8.2 million for the three and six months ended July 4, 2025 and \$2.0 million and \$3.0 million for the three and six months ended June 28, 2024, respectively, of non-recurring (non-Lima) acquisition integration costs and other non-recurring project costs for global ERP rationalization and shared service center start-up, and (iii) \$0.3 million and \$0.8 million for the three and six months ended July 4, 2025 and \$1.2 million and \$2.8 million for the three and six months ended June 28, 2024, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and

administrative expense on our Condensed Consolidated Statements of Operations.

(4) In the first and second quarters of 2025, we completed strategic purchases of economic interest on future royalty payments in our intellectual property ("royalty interest") for a fixed price of \$56.5 million, which will be paid over nine years. We accrued a liability and recognized a \$10.0 million and \$45.8 million charge for the net present value of the purchases for the three and six months ended July 4, 2025, respectively.

**Enovis Corporation**  
**Reconciliation of Gross Margin (GAAP) to Adjusted Gross Margin (non-GAAP)**  
Dollars in millions  
(Unaudited)

	Three Months Ended		Six Months Ended	
	July 4, 2025	June 28, 2024	July 4, 2025	June 28, 2024
Net sales	\$ 564.5	\$ 525.2	\$ 1,123.4	\$ 1,041.4
Gross profit	\$ 334.7	\$ 288.9	\$ 666.9	\$ 586.8
Gross profit margin (GAAP)	59.3 %	55.0 %	59.4 %	56.3 %
Gross profit (GAAP)	\$ 334.7	\$ 288.9	\$ 666.9	\$ 586.8
Inventory step-up and PPE step-up depreciation	6.6	23.9	19.2	29.0
Restructuring charges	0.2	—	0.3	—
Adjusted gross profit (Non-GAAP)	\$ 341.5	\$ 312.8	\$ 686.4	\$ 615.8
Adjusted gross profit margin (Non-GAAP)	60.5 %	59.6 %	61.1 %	59.1 %

**Enovis Corporation**  
**Condensed Consolidated Balance Sheets**  
Dollars in thousands, except share amounts  
(Unaudited)

	July 4, 2025	December 31, 2024
<b>ASSETS</b>		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 44,074	\$ 48,167
Trade receivables, less allowance for credit losses of \$28,178 and \$24,466	453,702	407,031
Inventories, net	628,215	547,120
Prepaid expenses	43,775	36,246
Other current assets	110,585	107,882
Total current assets	1,280,351	1,146,446
Property, plant and equipment, net	460,130	404,500
Goodwill	1,781,326	1,692,709
Intangible assets, net	1,341,995	1,317,429
Lease asset - right of use	65,183	68,915
Other assets	92,413	88,778
Total assets	\$ 5,021,398	\$ 4,718,777
<b>LIABILITIES AND EQUITY</b>		
CURRENT LIABILITIES:		
Current portion of long-term debt	\$ 20,029	\$ 20,027
Accounts payable	212,016	179,098
Accrued liabilities	336,139	329,873
Total current liabilities	568,184	528,998
Long-term debt, less current portion	1,373,510	1,309,473
Non-current lease liability	48,185	52,461
Other liabilities	450,559	263,516
Total liabilities	2,440,438	2,154,448
Equity:		
Common stock, \$0.001 par value; 133,333,333 shares authorized; 57,159,478 and 55,876,517 shares issued and outstanding as of July 4, 2025 and December 31, 2024, respectively	57	56
Additional paid-in capital	3,031,093	2,973,121
Accumulated deficit	(375,728)	(283,023)
Accumulated other comprehensive loss	(77,235)	(127,892)
Total Enovis Corporation equity	2,578,187	2,562,262
Noncontrolling interest	2,773	2,067
Total equity	2,580,960	2,564,329
Total liabilities and equity	\$ 5,021,398	\$ 4,718,777

**Enovis Corporation**  
**Condensed Consolidated Statements of Cash Flows**  
**Dollars in thousands**  
**(Unaudited)**

	<b>Six Months Ended</b>	
	<b>July 4, 2025</b>	<b>June 28, 2024</b>
<b>Cash flows from operating activities:</b>		
Net loss	\$ (92,253)	\$ (90,353)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	142,986	139,167
Stock-based compensation expense	16,075	14,102
Non-cash interest expense	3,203	2,558
Fair value loss (gain) on contingent acquisition shares	1,787	(20,068)
Loss on currency hedges	—	11,123
Deferred income tax expense (benefit)	(3,673)	(19,412)
Loss on sale of property, plant and equipment	848	383
Changes in operating assets and liabilities:		
Trade receivables, net	(20,824)	(24,807)
Inventories, net	(57,282)	1,953
Accounts payable	23,161	(6,744)
Other operating assets and liabilities	32,145	(41,840)
<b>Net cash provided by (used in) operating activities</b>	<b>46,173</b>	<b>(28,383)</b>
<b>Cash flows from investing activities:</b>		
Purchases of property, plant and equipment and intangibles	(87,631)	(76,333)
Payments for acquisitions, net of cash received, and investments	(24,290)	(758,190)
Cash received upon settlement of derivatives	1,601	(4,645)
<b>Net cash used in investing activities</b>	<b>(110,320)</b>	<b>(839,168)</b>
<b>Cash flows from financing activities:</b>		
Proceeds from borrowings on term credit facility	—	400,000
Repayments of borrowings under term credit facility	(10,000)	(15,000)
Proceeds from borrowings on revolving credit facilities and other	127,000	940,000
Repayments of borrowings on revolving credit facilities and other	(54,995)	(446,479)
Payment of debt issuance costs	—	(703)
Payments of tax withholding for stock-based awards	(3,447)	(4,772)
Proceeds from issuance of common stock, net	1,129	1,177
Deferred consideration payments and other	(2,265)	(7,174)
<b>Net cash provided by financing activities</b>	<b>57,422</b>	<b>867,049</b>
<b>Effect of foreign exchange rates on Cash and cash equivalents</b>	<b>2,632</b>	<b>(906)</b>
Decrease in Cash and cash equivalents	(4,093)	(1,408)
Cash and cash equivalents, beginning of period	48,167	44,832
<b>Cash and cash equivalents, end of period</b>	<b>\$ 44,074</b>	<b>\$ 43,424</b>
<b>Supplemental disclosures:</b>		
Fair value of contingently issuable shares in business acquisition	\$ —	\$ 107,877

**Enovis Corporation**  
**Change in Net Sales**  
**Dollars in millions**  
**(Unaudited)**

	<b>Net Sales</b>						
	<b>Prevention and Recovery</b>		<b>Reconstructive</b>			<b>Total Enovis</b>	
	<b>\$</b>	<b>Change %</b>	<b>\$</b>	<b>Change %</b>	<b>\$</b>	<b>Change %</b>	
For the three months ended June 28, 2024	\$ 277.8		\$ 247.4		\$ 525.2		
<i>Components of Change:</i>							
Existing Businesses <sup>(1)</sup>	7.2	2.6 %	20.0	8.1 %	27.1	5.2 %	
Acquisitions <sup>(2)</sup>	1.7	0.6 %	—	— %	1.7	0.3 %	
Divestitures <sup>(3)</sup>	—	— %	—	— %	—	— %	
Foreign Currency Translation <sup>(4)</sup>	3.9	1.4 %	6.6	2.7 %	10.5	2.0 %	

	12.8	4.6	%	26.6	10.8	%	39.3	7.5	%
For the three months ended July 4, 2025	<u>\$ 290.6</u>			<u>\$ 274.0</u>			<u>\$ 564.5</u>		

<b>Net Sales</b>											
<b>Prevention and Recovery</b>											
<b>Reconstructive</b>											
<b>Total Enovis</b>											
	<b>\$</b>	<b>Change %</b>			<b>\$</b>	<b>Change %</b>			<b>\$</b>	<b>Change %</b>	
For the six months ended June 28, 2024	\$ 536.8				\$ 504.7				\$ 1,041.4		
<i>Components of Change:</i>											
Existing Businesses <sup>(1)</sup>	27.2	5.1	%		52.8	10.5	%		80.1	7.7	%
Acquisitions <sup>(2)</sup>	1.7	0.3	%		—		%		1.7	0.2	%
Divestitures <sup>(3)</sup>	(4.3)	(0.8)	%		—		%		(4.3)	(0.4)	%
Foreign Currency Translation <sup>(4)</sup>	1.8	0.3	%		2.7	0.5	%		4.5	0.4	%
	<u>26.4</u>	<u>4.9</u>	<u>%</u>		<u>55.5</u>	<u>11.0</u>	<u>%</u>		<u>82.0</u>	<u>7.9</u>	<u>%</u>
For the six months ended July 4, 2025	<u>\$ 563.2</u>				<u>\$ 560.2</u>				<u>\$ 1,123.4</u>		

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of change due to factors such as price, product mix and volume.

(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.

(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.

(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.